Related Experiment Video
Updated: Oct 29, 2025

Swimming Induced Paralysis to Assess Dopamine Signaling in Caenorhabditis elegans
Published on: April 3, 2019
Hypokalaemic Paralysis Associated with COVID-19 Infection
Atul Kaushik1, Anish Garg1, Brinder Mohan Singh2
1Post Graduate Resident, SMS and R, Sharda Hospital, Sharda University, Greater Noida, Uttar Pradesh.
Introduction:
COVID-19 is a pandemic affecting mainly respiratory and gastrointestinal system. Severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) binds angiotensin converting enzyme 2 (ACE-2) of renin-angiotensin system (RAS) resulting in hypokalaemia. We hereby report the a of hypokalaemic paralysis induced by COVID-19.
Case:
A 56 years old male with no co-morbidities presented with fever (2days), weakness in bilateral lower limbs (1 day). His had severe hypokalaemia with serum potassium of 2.05 mEq/L. RT-PCR of nasopharyngeal swab for SARS-CoV- 19 was positive. He was diagnosed as a case of hypokalaemic paralysis induced by COVID-19 infection.
Conclusion:
We suggest that during this pandemic era if a COVID-19 patient presents with paralysis, hypokalaemia induced paralysis should be kept in the differential diagnosis.
What Is Known:
COVID-19 infection leads to hypokalemia.
What Is New:
Hypokalaemic paralysis as a manifestation of COVID-19.
More Related Videos
Related Concept Videos
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Acute Respiratory Failure-III
Depolarizing Blockers: Pharmocokinetics
Chronic Kidney Disease II: Clinical Manifestations
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...

